{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:15:33Z","timestamp":1792422933356,"version":"4.5.0"},"reference-count":220,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Cancer stem cells (CSCs) are pivotal in tumor initiation, progression, and relapse, underscoring the need for targeted therapies to achieve lasting responses. This review delves into CSC biology, highlighting their tumor-initiating potential demonstrated through limiting dilution assays and their role in resistance to therapies. Although successful CAR therapies, such as anti-CD19 CAR T-cells, can induce complete responses without directly targeting CSCs, CAR strategies focusing on CSCs may offer promising avenues to prevent recurrence. We assess CAR therapies targeting CSC-specific antigens, including CD133 and GD2, in preclinical and clinical contexts, emphasizing their effectiveness against glioblastoma, breast cancer, and other malignancies. Nevertheless, challenges such as marker specificity and suppression by the tumor microenvironment (TME) persist. Future strategies, which may include dual-targeting and AI-driven marker discovery, aim to improve CSC elimination and advance personalized cancer immunotherapy.<\/jats:p>","DOI":"10.1186\/s12935-025-03846-3","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T10:04:29Z","timestamp":1753697069000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Targeting cancer stem cells with CAR-based immunotherapy: biology, evidence, and future directions"],"prefix":"10.1186","volume":"25","author":[{"given":"Kaveh","family":"Hadiloo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parsa","family":"Mostanadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Asadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siavash","family":"Taremi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdolreza","family":"Esmaeilzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"issue":"24","key":"3846_CR1","doi-asserted-by":"publisher","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","volume":"86","author":"G Gross","year":"1989","unstructured":"Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A. 1989;86(24):10024\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3846_CR2","doi-asserted-by":"crossref","unstructured":"Hadiloo K, Taremi S, Safa SH, Amidifar S, Esmaeilzadeh A. The new era of immunological treatment, last updated and future consideration of CAR T cell-based drugs. Pharmacol Res. 2024;107158.","DOI":"10.1016\/j.phrs.2024.107158"},{"key":"3846_CR3","doi-asserted-by":"crossref","unstructured":"Fatima K, Jan S, Malik F, Khan SU. Role of Cancer stem cells in drug resistance. drug resistance.in cancer: mechanisms and strategies. Springer; 2024. pp. 77\u2013120.","DOI":"10.1007\/978-981-97-1666-1_3"},{"issue":"1","key":"3846_CR4","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41392-024-01851-y","volume":"9","author":"X Chu","year":"2024","unstructured":"Chu X, Tian W, Ning J, Xiao G, Zhou Y, Wang Z, et al. Cancer stem cells: advances in knowledge and implications for cancer therapy. Signal Transduct Target Therapy. 2024;9(1):170.","journal-title":"Signal Transduct Target Therapy"},{"key":"3846_CR5","doi-asserted-by":"publisher","first-page":"1441081","DOI":"10.3389\/fcell.2024.1441081","volume":"12","author":"H Han","year":"2024","unstructured":"Han H, He T, Wu Y, He T, Zhou W. Multidimensional analysis of tumor stem cells: from biological properties, metabolic adaptations to immune escape mechanisms. Front Cell Dev Biology. 2024;12:1441081.","journal-title":"Front Cell Dev Biology"},{"issue":"1","key":"3846_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41392-020-00430-1","volume":"6","author":"H-M Zhou","year":"2021","unstructured":"Zhou H-M, Zhang J-G, Zhang X, Li Q. Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents. Signal Transduct Target Therapy. 2021;6(1):62.","journal-title":"Signal Transduct Target Therapy"},{"issue":"7015","key":"3846_CR7","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature03128","volume":"432","author":"SK Singh","year":"2004","unstructured":"Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature. 2004;432(7015):396\u2013401.","journal-title":"Nature"},{"issue":"3","key":"3846_CR8","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3390\/cancers11030345","volume":"11","author":"SM Afify","year":"2019","unstructured":"Afify SM, Seno M. Conversion of stem cells to cancer stem cells: undercurrent of cancer initiation. Cancers. 2019;11(3):345.","journal-title":"Cancers"},{"issue":"3","key":"3846_CR9","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/cr.2012.13","volume":"22","author":"DG Tang","year":"2012","unstructured":"Tang DG. Understanding cancer stem cell heterogeneity and plasticity. Cell Res. 2012;22(3):457\u201372.","journal-title":"Cell Res"},{"issue":"7","key":"3846_CR10","doi-asserted-by":"publisher","first-page":"4102","DOI":"10.3390\/ijms25074102","volume":"25","author":"MR MacLean","year":"2024","unstructured":"MacLean MR, Walker OL, Arun RP, Fernando W, Marcato P. Informed by Cancer stem cells of solid tumors: advances in treatments targeting Tumor-Promoting factors and pathways. Int J Mol Sci. 2024;25(7):4102.","journal-title":"Int J Mol Sci"},{"key":"3846_CR11","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.3389\/fimmu.2020.01280","volume":"11","author":"L Walcher","year":"2020","unstructured":"Walcher L, Kistenmacher AK, Suo H, Kitte R, Dluczek S, Strau\u00df A, et al. Cancer stem Cells-Origins and biomarkers: perspectives for targeted personalized therapies. Front Immunol. 2020;11:1280.","journal-title":"Front Immunol"},{"issue":"4","key":"3846_CR12","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.stem.2007.08.001","volume":"1","author":"M Todaro","year":"2007","unstructured":"Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, Iovino F, et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell. 2007;1(4):389\u2013402.","journal-title":"Cell Stem Cell"},{"issue":"10","key":"3846_CR13","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/nm1483","volume":"12","author":"L Jin","year":"2006","unstructured":"Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med. 2006;12(10):1167\u201374.","journal-title":"Nat Med"},{"key":"3846_CR14","doi-asserted-by":"publisher","first-page":"937327","DOI":"10.3389\/fimmu.2022.937327","volume":"13","author":"B Huang","year":"2022","unstructured":"Huang B, Miao L, Liu J, Zhang J, Li Y. A promising antitumor method: targeting CSC with immune cells modified with CAR. Front Immunol. 2022;13:937327.","journal-title":"Front Immunol"},{"issue":"21","key":"3846_CR15","doi-asserted-by":"publisher","first-page":"9891","DOI":"10.1111\/jcmm.16939","volume":"25","author":"X Cui","year":"2021","unstructured":"Cui X, Liu R, Duan L, Cao D, Zhang Q, Zhang A. CAR-T therapy: prospects in targeting cancer stem cells. J Cell Mol Med. 2021;25(21):9891\u2013904.","journal-title":"J Cell Mol Med"},{"issue":"4","key":"3846_CR16","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/ijlh.14121","volume":"45","author":"P Ramesh","year":"2023","unstructured":"Ramesh P, Hui HY, Brownrigg LM, Fuller KA, Erber WN. Chimeric antigen receptor T-cells: properties, production, and quality control. Int J Lab Hematol. 2023;45(4):425\u201335.","journal-title":"Int J Lab Hematol"},{"key":"3846_CR17","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.3389\/fimmu.2018.01717","volume":"9","author":"R Elahi","year":"2018","unstructured":"Elahi R, Khosh E, Tahmasebi S, Esmaeilzadeh A. Immune cell hacking: challenges and clinical approaches to create smarter generations of chimeric antigen receptor T cells. Front Immunol. 2018;9:1717.","journal-title":"Front Immunol"},{"issue":"1","key":"3846_CR18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s40364-023-00537-x","volume":"11","author":"K Hadiloo","year":"2023","unstructured":"Hadiloo K, Taremi S, Heidari M, Esmaeilzadeh A. The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors. Biomark Res. 2023;11(1):103.","journal-title":"Biomark Res"},{"issue":"1","key":"3846_CR19","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12935-023-02923-9","volume":"23","author":"K Hadiloo","year":"2023","unstructured":"Hadiloo K, Tahmasebi S, Esmaeilzadeh A. CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapy. Cancer Cell Int. 2023;23(1):86.","journal-title":"Cancer Cell Int"},{"key":"3846_CR20","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1007\/s12015-021-10246-3","volume":"17","author":"R Elahi","year":"2021","unstructured":"Elahi R, Heidary AH, Hadiloo K, Esmaeilzadeh A. Chimeric antigen receptor-engineered natural killer (CAR NK) cells in cancer treatment; recent advances and future prospects. Stem Cell Reviews Rep. 2021;17:2081\u2013106.","journal-title":"Stem Cell Reviews Rep"},{"issue":"1","key":"3846_CR21","doi-asserted-by":"publisher","first-page":"2248826","DOI":"10.1080\/2162402X.2023.2248826","volume":"12","author":"X Jin","year":"2023","unstructured":"Jin X, Xie D, Sun R, Lu W, Xiao X, Yu Y, et al. CAR-T cells dual-target CD123 and NKG2DLs to eradicate AML cells and selectively target immunosuppressive cells. Oncoimmunology. 2023;12(1):2248826.","journal-title":"Oncoimmunology"},{"issue":"1","key":"3846_CR22","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13046-021-01874-1","volume":"40","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Wang D, Peng M, Tang L, Ouyang J, Xiong F, et al. Single-cell RNA sequencing in cancer research. J Exp Clin Cancer Res. 2021;40(1):81.","journal-title":"J Exp Clin Cancer Res"},{"issue":"9","key":"3846_CR23","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/j.ccell.2024.08.005","volume":"42","author":"I Tirosh","year":"2024","unstructured":"Tirosh I, Suva ML. Cancer cell states: lessons from ten years of single-cell RNA-sequencing of human tumors. Cancer Cell. 2024;42(9):1497\u2013506.","journal-title":"Cancer Cell"},{"key":"3846_CR24","doi-asserted-by":"publisher","first-page":"842200","DOI":"10.3389\/fonc.2022.842200","volume":"12","author":"H Kumar","year":"2022","unstructured":"Kumar H, Mazumder S, Sharma N, Chakravarti S, Long MD, Meurice N, et al. Single-Cell proteomics and tumor RNAseq identify novel pathways associated with Clofazimine sensitivity in PI- and IMiD- resistant myeloma, and putative Stem-Like cells. Front Oncol. 2022;12:842200.","journal-title":"Front Oncol"},{"issue":"8","key":"3846_CR25","doi-asserted-by":"publisher","first-page":"5810","DOI":"10.15419\/bmrat.v10i8.823","volume":"10","author":"ON Hairuddin","year":"2023","unstructured":"Hairuddin ON, Yahaya BH, Ibahim MJ, Verakumarasivam A, Choy CS, Mazlan M, et al. Comparison of cancer stem cell enrichment between spheroids derived from single-cell and multicellular aggregate cultures. Biomedical Res Therapy. 2023;10(8):5810\u201330.","journal-title":"Biomedical Res Therapy"},{"issue":"4","key":"3846_CR26","doi-asserted-by":"publisher","first-page":"511","DOI":"10.5966\/sctm.2015-0214","volume":"5","author":"ML De Angelis","year":"2016","unstructured":"De Angelis ML, Zeuner A, Policicchio E, Russo G, Bruselles A, Signore M, et al. Cancer stem Cell-Based models of colorectal Cancer reveal molecular determinants of therapy resistance. Stem Cells Transl Med. 2016;5(4):511\u201323.","journal-title":"Stem Cells Transl Med"},{"key":"3846_CR27","doi-asserted-by":"crossref","unstructured":"Kenderian SS, Ruella M, Shestova O, Klichinsky M, Kim MY, Soderquist C, et al. Leukemia stem cells are characterized by CLEC12A expression and chemotherapy refractoriness that can be overcome by targeting with chimeric antigen receptor T cells. American Society of Hematology Washington, DC; 2016.","DOI":"10.1182\/blood.V128.22.766.766"},{"issue":"1","key":"3846_CR28","doi-asserted-by":"publisher","first-page":"1683345","DOI":"10.1080\/2162402X.2019.1683345","volume":"9","author":"CM Seitz","year":"2020","unstructured":"Seitz CM, Schroeder S, Knopf P, Krahl AC, Hau J, Schleicher S, et al. GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells. Oncoimmunology. 2020;9(1):1683345.","journal-title":"Oncoimmunology"},{"issue":"2","key":"3846_CR29","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1089\/scd.2008.0124","volume":"18","author":"GS-L Peh","year":"2009","unstructured":"Peh GS-L, Lang RJ, Pera MF, Hawes SM. CD133 expression by neural progenitors derived from human embryonic stem cells and its use for their prospective isolation. Stem Cells Dev. 2009;18(2):269\u201382.","journal-title":"Stem Cells Dev"},{"issue":"11","key":"3846_CR30","doi-asserted-by":"publisher","first-page":"e78897","DOI":"10.1371\/journal.pone.0078897","volume":"8","author":"GJ Schuurhuis","year":"2013","unstructured":"Schuurhuis GJ, Meel MH, Wouters F, Min LA, Terwijn M, de Jonge NA, et al. Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells. PLoS ONE. 2013;8(11):e78897.","journal-title":"PLoS ONE"},{"issue":"1","key":"3846_CR31","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","volume":"41","author":"K Pan","year":"2022","unstructured":"Pan K, Farrukh H, Chittepu VCSR, Xu H, Pan C-x, Zhu Z. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Experimental Clin Cancer Res. 2022;41(1):119.","journal-title":"J Experimental Clin Cancer Res"},{"key":"3846_CR32","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1146\/annurev-cancerbio-061521-082320","volume":"7","author":"MJ Raftery","year":"2023","unstructured":"Raftery MJ, Franz\u00e9n AS, Pecher G. CAR NK cells: the future is now. Annual Rev Cancer Biology. 2023;7:229\u201346.","journal-title":"Annual Rev Cancer Biology"},{"issue":"6","key":"3846_CR33","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, et al. Use of CAR-Transduced natural killer cells in CD19-Positive lymphoid tumors. N Engl J Med. 2020;382(6):545\u201353.","journal-title":"N Engl J Med"},{"key":"3846_CR34","doi-asserted-by":"crossref","unstructured":"Hosseinalizadeh H, Wang LS, Mirzaei H, Amoozgar Z, Tian L, Yu J. Emerging combined CAR-NK cell therapies in cancer treatment: finding a dancing partner. Mol Ther. 2025.","DOI":"10.1016\/j.ymthe.2024.12.057"},{"key":"3846_CR35","doi-asserted-by":"crossref","unstructured":"Rojas-Quintero J, D\u00edaz MP, Palmar J, Galan-Freyle NJ, Morillo V, Escalona D et al. Car T cells in solid tumors: overcoming Obstacles. Int J Mol Sci. 2024;25(8).","DOI":"10.3390\/ijms25084170"},{"issue":"10","key":"3846_CR36","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","volume":"21","author":"L Peng","year":"2024","unstructured":"Peng L, Sferruzza G, Yang L, Zhou L, Chen S. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell Mol Immunol. 2024;21(10):1089\u2013108.","journal-title":"Cell Mol Immunol"},{"issue":"10","key":"3846_CR37","doi-asserted-by":"publisher","first-page":"3672","DOI":"10.1172\/JCI84427","volume":"126","author":"A-T Henze","year":"2016","unstructured":"Henze A-T, Mazzone M. The impact of hypoxia on tumor-associated macrophages. J Clin Investig. 2016;126(10):3672\u20139.","journal-title":"J Clin Investig"},{"key":"3846_CR38","doi-asserted-by":"crossref","unstructured":"Peter Valent KB, Irina Sadovnik D, Smiljkovic D, Ivanov H, Herrmann Y, Filik G, et al. Cell-based and antibody-mediated immunotherapies directed against leukemic stem cells in acute myeloid leukemia: perspectives and open issues. Stem Cells Transl Med. 2020;9:1331\u201343.","DOI":"10.1002\/sctm.20-0147"},{"issue":"12","key":"3846_CR39","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1182\/bloodadvances.2022008762","volume":"7","author":"VM Perriello","year":"2023","unstructured":"Perriello VM, Rotiroti MC, Pisani I, Galimberti S, Alberti G, Pianigiani G, et al. IL-3-zetakine combined with a CD33 costimulatory receptor as a dual CAR approach for safer and selective targeting of AML. Blood Adv. 2023;7(12):2855\u201371.","journal-title":"Blood Adv"},{"key":"3846_CR40","doi-asserted-by":"publisher","unstructured":"Wang H, Feng S, Zhu Y, Zhang Y, Zhou Z, Nian Z, et al. The tandem CD33-CLL1 CAR-T as an approach to treat acute myeloid leukemia: the tandem CLL1\/CD33 CAR-T to treat AML. Blood Transfus. 2024. https:\/\/doi.org\/10.2450\/BloodTransfus.786.","DOI":"10.2450\/BloodTransfus.786"},{"key":"3846_CR41","doi-asserted-by":"crossref","unstructured":"Yan Z, Gu R, Ma H, Chen N, Zhang T, Xu Y, et al. A dual-targeting approach with anti-IL10R CAR-T cells engineered to release anti-CD33 bispecific antibody in enhancing killing effect on acute myeloid leukemia cells. Cell Oncol. 2024;47:1879\u201395. 1\u201317.","DOI":"10.1007\/s13402-024-00971-5"},{"key":"3846_CR42","doi-asserted-by":"publisher","first-page":"3449","DOI":"10.1182\/blood-2023-180890","volume":"142","author":"Y Wang","year":"2023","unstructured":"Wang Y, Lu W, Rohrbacher L, Flaswinkel H, Emhardt AJ, Magno G, et al. CD33-TIM3 dual CAR T cells: enhancing specificity while maintaining efficacy against AML. Blood. 2023;142:3449.","journal-title":"Blood"},{"key":"3846_CR43","doi-asserted-by":"crossref","unstructured":"Appelbaum J, Price AE, Oda K, Zhang J, Leung W-H, Tampella G et al. Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized Rapamycin dosing. J Clin Investig. 2024;134(9).","DOI":"10.1172\/JCI162593"},{"key":"3846_CR44","doi-asserted-by":"crossref","unstructured":"Teppert K, Ogusuku IEY, Brandes C, Herbel V, Winter N, Werchau N et al. CAR\u2019TCR-T cells co-expressing CD33-CAR and dNPM1-TCR as superior dual-targeting approach for AML treatment. Mol Therapy Oncol. 2024;32(2).","DOI":"10.1016\/j.omton.2024.200797"},{"key":"3846_CR45","doi-asserted-by":"crossref","unstructured":"Fiorenza S, Lim SY, Laszlo GS, Kimble EL, Phi T-D, Lunn-Halbert MC et al. Targeting the membrane-proximal C2-set domain of CD33 for improved CAR T cell therapy. Mol Therapy Oncol. 2024;32(3).","DOI":"10.1016\/j.omton.2024.200854"},{"issue":"Supplement 1","key":"3846_CR46","doi-asserted-by":"publisher","first-page":"4558","DOI":"10.1182\/blood-2022-169758","volume":"140","author":"N Albinger","year":"2022","unstructured":"Albinger N, Bexte T, Buchinger L, Wendel P, Al-Ajami A, Gessner A, et al. CRISPR\/Cas9 gene editing of immune checkpoint receptor NKG2A improves the efficacy of primary CD33-CAR-NK cells against AML. Blood. 2022;140(Supplement 1):4558\u20139.","journal-title":"Blood"},{"issue":"Supplement 1","key":"3846_CR47","doi-asserted-by":"publisher","first-page":"12685","DOI":"10.1182\/blood-2022-166420","volume":"140","author":"Y Wang","year":"2022","unstructured":"Wang Y, Wang L, Shao M, He X, Yue Y, Zhou Y, et al. Off-the-Shelf, multiplexed-engineered iPSC-derived CD33 CAR-NK cells for treatment of acute myeloid leukemia. Blood. 2022;140(Supplement 1):12685.","journal-title":"Blood"},{"issue":"1","key":"3846_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40164-024-00592-6","volume":"14","author":"R Huang","year":"2025","unstructured":"Huang R, Wang X, Yan H, Tan X, Ma Y, Wang M, et al. Safety and efficacy of CD33-targeted CAR-NK cell therapy for relapsed\/refractory AML: preclinical evaluation and phase I trial. Experimental Hematol Oncol. 2025;14(1):1.","journal-title":"Experimental Hematol Oncol"},{"issue":"3","key":"3846_CR49","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.hoc.2020.01.004","volume":"34","author":"M Sugita","year":"2020","unstructured":"Sugita M, Guzman ML. CD123 as a therapeutic target against malignant stem cells. Hematology\/Oncology Clin. 2020;34(3):553\u201364.","journal-title":"Hematology\/Oncology Clin"},{"key":"3846_CR50","doi-asserted-by":"publisher","first-page":"101695","DOI":"10.1016\/j.tranon.2023.101695","volume":"34","author":"D Xie","year":"2023","unstructured":"Xie D, Jin X, Sun R, Zhang M, Lu W, Cao X, et al. Bicistronic CAR-T cells targeting CD123 and CLL1 for AML to reduce the risk of antigen escape. Translational Oncol. 2023;34:101695.","journal-title":"Translational Oncol"},{"key":"3846_CR51","doi-asserted-by":"crossref","unstructured":"Boucher JC, Shrestha B, Vishwasrao P, Leick M, Cervantes EV, Ghafoor T et al. Bispecific CD33\/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia. Mol Therapy-Oncolytics. 2023;31.","DOI":"10.1016\/j.omto.2023.100751"},{"issue":"3","key":"3846_CR52","doi-asserted-by":"publisher","first-page":"S253","DOI":"10.1016\/j.bbmt.2016.12.423","volume":"23","author":"C Sinha","year":"2017","unstructured":"Sinha C, Seth A, Kahali B, Cunningham L. Development and evaluation of NK-CD123 CAR against high risk acute myeloid leukemia. Biol Blood Marrow Transplant. 2017;23(3):S253.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"3846_CR53","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13045-022-01376-3","volume":"15","author":"S Caruso","year":"2022","unstructured":"Caruso S, De Angelis B, Del Bufalo F, Ciccone R, Donsante S, Volpe G, et al. Safe and effective off-the-shelf immunotherapy based on CAR. CD123-NK cells for the treatment of acute myeloid leukaemia. J Hematol Oncol. 2022;15(1):163.","journal-title":"J Hematol Oncol"},{"key":"3846_CR54","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1182\/blood-2023-179086","volume":"142","author":"X Zhang","year":"2023","unstructured":"Zhang X, Yang J, Li J, Qiu L, Liu Sr H, Xiong M, et al. Naturally selected CD7-targeted chimeric antigen receptor (CAR)-T cell therapy for refractory\/relapsed acute myeloid leukemia: phase I clinical trial. Blood. 2023;142:218.","journal-title":"Blood"},{"issue":"1","key":"3846_CR55","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ymthe.2022.09.003","volume":"31","author":"N Watanabe","year":"2023","unstructured":"Watanabe N, Mo F, Zheng R, Ma R, Bray VC, van Leeuwen DG, et al. Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies. Mol Ther. 2023;31(1):24\u201334.","journal-title":"Mol Ther"},{"issue":"3","key":"3846_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/mmr.2021.11847","volume":"23","author":"G Lin","year":"2021","unstructured":"Lin G, Zhang Y, Yu L, Wu D. Cytotoxic effect of CLL\u20131 CAR\u2013T cell immunotherapy with PD\u20131 Silencing on relapsed\/refractory acute myeloid leukemia. Mol Med Rep. 2021;23(3):1.","journal-title":"Mol Med Rep"},{"key":"3846_CR57","doi-asserted-by":"crossref","unstructured":"Atilla PA, McKenna MK, Tashiro H, Srinivasan M, Mo F, Watanabe N et al. Modulating TNF\u03b1 activity allows Transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia. J Immunother Cancer. 2020;8(2).","DOI":"10.1136\/jitc-2020-001229"},{"key":"3846_CR58","doi-asserted-by":"crossref","unstructured":"Li J, Liu K, Xu G, Chen S, Zhang Y. Intracellular retention of TCR\u03b1\u03b2\/CD3 to generate novel allogeneic CAR-T cells targeting CLL1 for treating acute myelocytic leukemia. American Society of Clinical Oncology; 2024.","DOI":"10.1200\/JCO.2024.42.16_suppl.e14532"},{"key":"3846_CR59","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1182\/blood-2021-147244","volume":"138","author":"M Gurney","year":"2021","unstructured":"Gurney M, O\u2019Reilly E, Corcoran S, Brophy S, Hardwicke D, Krawczyk J, et al. Tc buster transposon engineered CLL-1 CAR-NK cells efficiently target acute myeloid leukemia. Blood. 2021;138:1725.","journal-title":"Blood"},{"issue":"16","key":"3846_CR60","doi-asserted-by":"publisher","first-page":"4418","DOI":"10.1182\/bloodadvances.2022007059","volume":"7","author":"T Glisovic-Aplenc","year":"2023","unstructured":"Glisovic-Aplenc T, Diorio C, Chukinas JA, Veliz K, Shestova O, Shen F, et al. CD38 as a pan-hematologic target for chimeric antigen receptor T cells. Blood Adv. 2023;7(16):4418\u201330.","journal-title":"Blood Adv"},{"issue":"5","key":"3846_CR61","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1021\/acs.molpharmaceut.2c00913","volume":"20","author":"N An","year":"2023","unstructured":"An N, Pan Y, Yang L, Zhang Q, Deng S, Zhang Q, et al. Anti-acute myeloid leukemia activity of CD38-CAR-T cells with PI3K\u03b4 downregulation. Mol Pharm. 2023;20(5):2426\u201335.","journal-title":"Mol Pharm"},{"issue":"2","key":"3846_CR62","first-page":"615","volume":"12","author":"Y-J Ma","year":"2022","unstructured":"Ma Y-J, Dai H-P, Cui Q-Y, Cui W, Zhu W-J, Qu C-J, et al. Successful application of PD-1 knockdown CLL-1 CAR-T therapy in two AML patients with post-transplant relapse and failure of anti-CD38 CAR-T cell treatment. Am J Cancer Res. 2022;12(2):615.","journal-title":"Am J Cancer Res"},{"issue":"4","key":"3846_CR63","doi-asserted-by":"publisher","first-page":"100032","DOI":"10.1016\/j.bneo.2024.100032","volume":"1","author":"E Troy","year":"2024","unstructured":"Troy E, Caporale J, Sezgin Y, Pereira MS, Behbehani G, Lyberger J, et al. CD38-CAR human NK cells in combination with ATRA enhance cytotoxicity against CD38-expressing hematologic malignancies. Blood Neoplasia. 2024;1(4):100032.","journal-title":"Blood Neoplasia"},{"key":"3846_CR64","doi-asserted-by":"publisher","first-page":"1145441","DOI":"10.3389\/fimmu.2023.1145441","volume":"14","author":"L Tang","year":"2023","unstructured":"Tang L, Kong Y, Wang H, Zou P, Sun T, Liu Y, et al. Demethylating therapy increases cytotoxicity of CD44v6 CAR-T cells against acute myeloid leukemia. Front Immunol. 2023;14:1145441.","journal-title":"Front Immunol"},{"issue":"2","key":"3846_CR65","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3324\/haematol.2022.281456","volume":"108","author":"LM Niswander","year":"2023","unstructured":"Niswander LM, Graff ZT, Chien CD, Chukinas JA, Meadows CA, Leach LC, et al. Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against FLT3-mutant acute myeloid leukemia and KMT2A-rearranged acute lymphoblastic leukemia. Haematologica. 2023;108(2):457.","journal-title":"Haematologica"},{"issue":"20","key":"3846_CR66","doi-asserted-by":"publisher","first-page":"6225","DOI":"10.1182\/bloodadvances.2022007405","volume":"7","author":"AG Mansour","year":"2023","unstructured":"Mansour AG, Teng K-Y, Li Z, Zhu Z, Chen H, Tian L, et al. Off-the-shelf CAR\u2013engineered natural killer cells targeting FLT3 enhance killing of acute myeloid leukemia. Blood Adv. 2023;7(20):6225\u201339.","journal-title":"Blood Adv"},{"key":"3846_CR67","first-page":"27","volume":"202409","author":"F Chen","year":"2024","unstructured":"Chen F, Lv M-H, Li C-W, Zhang Y-Q, Yuan Z, Wei Z-X, et al. Pexidartinib plus FLT3-directed CAR-Macrophage for the treatment of FLT3-ITD-mutated acute myeloid leukemia in preclinical model. BioRxiv. 2024;202409:27\u2013615313.","journal-title":"BioRxiv"},{"key":"3846_CR68","doi-asserted-by":"crossref","unstructured":"Trad R, Warda W, Alcazer V, da Rocha MN, Berceanu A, Nicod C et al. Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia. J Immunother Cancer. 2022;10(7).","DOI":"10.1136\/jitc-2021-004222"},{"issue":"24","key":"3846_CR69","doi-asserted-by":"publisher","first-page":"5805","DOI":"10.3390\/jcm10245805","volume":"10","author":"M Houshmand","year":"2021","unstructured":"Houshmand M, Kazemi A, Anjam Najmedini A, Ali MS, Gaidano V, Cignetti A, et al. Shedding light on targeting chronic myeloid leukemia stem cells. J Clin Med. 2021;10(24):5805.","journal-title":"J Clin Med"},{"key":"3846_CR70","doi-asserted-by":"publisher","first-page":"1309010","DOI":"10.3389\/fimmu.2023.1309010","volume":"14","author":"J Imeri","year":"2024","unstructured":"Imeri J, Marcoux P, Huyghe M, Desterke C, Fantacini DMC, Griscelli F, et al. Chimeric antigen-receptor (CAR) engineered natural killer cells in a chronic myeloid leukemia (CML) blast crisis model. Front Immunol. 2024;14:1309010.","journal-title":"Front Immunol"},{"key":"3846_CR71","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40164-025-00608-9","volume":"14","author":"J Guoyun","year":"2025","unstructured":"Guoyun J, Yuefeng Q, Zhenglan H, Zuowei Y, Hongyan Z, Ying Y, et al. CAR-macrophages targets CD26 to eliminate chronic myeloid leukemia stem cells. Experimental Hematol Oncol. 2025;14:14.","journal-title":"Experimental Hematol Oncol"},{"issue":"14","key":"3846_CR72","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.3390\/cancers13143523","volume":"13","author":"W Guo","year":"2021","unstructured":"Guo W, Wang H, Chen P, Shen X, Zhang B, Liu J, et al. Identification and characterization of multiple myeloma stem cell-like cells. Cancers. 2021;13(14):3523.","journal-title":"Cancers"},{"issue":"1","key":"3846_CR73","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jocit.2014.11.001","volume":"2","author":"B Guo","year":"2016","unstructured":"Guo B, Chen M, Han Q, Hui F, Dai H, Zhang W, et al. CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma. J Cell Immunotherapy. 2016;2(1):28\u201335.","journal-title":"J Cell Immunotherapy"},{"key":"3846_CR74","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3389\/fonc.2017.00218","volume":"7","author":"SH Tan","year":"2017","unstructured":"Tan SH, Bertulfo FC, Sanda T. Leukemia-initiating cells in T-cell acute lymphoblastic leukemia. Front Oncol. 2017;7:218.","journal-title":"Front Oncol"},{"issue":"aop","key":"3846_CR75","first-page":"1","volume":"1","author":"A Gardenswartz","year":"2024","unstructured":"Gardenswartz A, Cairo MS. Therapy for relapsed\/refractory B-Cell Non-Hodgkin lymphoma in children, adolescents, and young adults. J Natl Compr Canc Netw. 2024;1(aop):1\u20137.","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"3846_CR76","doi-asserted-by":"publisher","first-page":"211","DOI":"10.5045\/kjh.2011.46.4.211","volume":"46","author":"SJ Kim","year":"2011","unstructured":"Kim SJ. Lymphoma stem cells: A step toward a new therapeutic target. Korean J Hematol. 2011;46(4):211\u20133.","journal-title":"Korean J Hematol"},{"key":"3846_CR77","doi-asserted-by":"publisher","first-page":"123015","DOI":"10.1016\/j.lfs.2024.123015","volume":"355","author":"MA Sarabia-S\u00e1nchez","year":"2024","unstructured":"Sarabia-S\u00e1nchez MA, Tinajero-Rodr\u00edguez JM, Ortiz-S\u00e1nchez E, Alvarado-Ortiz E. Cancer stem cell markers: symphonic masters of chemoresistance and immune evasion. Life Sci. 2024;355:123015.","journal-title":"Life Sci"},{"issue":"9","key":"3846_CR78","doi-asserted-by":"publisher","first-page":"4602","DOI":"10.3390\/ijms23094602","volume":"23","author":"SMB Rodriguez","year":"2022","unstructured":"Rodriguez SMB, Staicu G-A, Sevastre A-S, Baloi C, Ciubotaru V, Dricu A, et al. Glioblastoma stem Cells\u2014Useful tools in the battle against Cancer. Int J Mol Sci. 2022;23(9):4602.","journal-title":"Int J Mol Sci"},{"key":"3846_CR79","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3389\/fgene.2020.00312","volume":"11","author":"RY Alhabbab","year":"2020","unstructured":"Alhabbab RY. Targeting cancer stem cells by genetically engineered chimeric antigen receptor T cells. Front Genet. 2020;11:312.","journal-title":"Front Genet"},{"issue":"1","key":"3846_CR80","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41698-021-00233-9","volume":"5","author":"M Prapa","year":"2021","unstructured":"Prapa M, Chiavelli C, Golinelli G, Grisendi G, Bestagno M, Di Tinco R, et al. GD2 CAR T cells against human glioblastoma. NPJ Precision Oncol. 2021;5(1):93.","journal-title":"NPJ Precision Oncol"},{"issue":"1","key":"3846_CR81","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12943-022-01711-9","volume":"22","author":"Z Liu","year":"2023","unstructured":"Liu Z, Zhou J, Yang X, Liu Y, Zou C, Lv W, et al. Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma. Mol Cancer. 2023;22(1):3.","journal-title":"Mol Cancer"},{"key":"3846_CR82","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ebiom.2019.08.030","volume":"47","author":"D Nehama","year":"2019","unstructured":"Nehama D, Di Ianni N, Musio S, Du H, Patan\u00e9 M, Pollo B, et al. B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres. EBioMedicine. 2019;47:33\u201343.","journal-title":"EBioMedicine"},{"key":"3846_CR83","doi-asserted-by":"publisher","first-page":"669071","DOI":"10.3389\/fonc.2021.669071","volume":"11","author":"JS Durgin","year":"2021","unstructured":"Durgin JS, Henderson F Jr, Nasrallah MP, Mohan S, Wang S, Lacey SF, et al. Case report: prolonged survival following EGFRvIII CAR T cell treatment for recurrent glioblastoma. Front Oncol. 2021;11:669071.","journal-title":"Front Oncol"},{"issue":"3","key":"3846_CR84","doi-asserted-by":"publisher","first-page":"e1440","DOI":"10.1002\/cti2.1440","volume":"12","author":"RC Abbott","year":"2023","unstructured":"Abbott RC, Iliopoulos M, Watson KA, Arcucci V, Go M, Hughes-Parry HE, et al. Human EGFRvIII chimeric antigen receptor T cells demonstrate favorable safety profile and curative responses in orthotopic glioblastoma. Clin Translational Immunol. 2023;12(3):e1440.","journal-title":"Clin Translational Immunol"},{"issue":"1","key":"3846_CR85","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1186\/s12967-023-04330-0","volume":"21","author":"S Wang","year":"2023","unstructured":"Wang S, Wei W, Yuan Y, Sun B, Yang D, Liu N, et al. Chimeric antigen receptor T cells targeting cell surface GRP78 efficiently kill glioblastoma and cancer stem cells. J Translational Med. 2023;21(1):493.","journal-title":"J Translational Med"},{"issue":"1","key":"3846_CR86","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s40425-019-0642-9","volume":"7","author":"D Yang","year":"2019","unstructured":"Yang D, Sun B, Dai H, Li W, Shi L, Zhang P, et al. T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells. J Immunother Cancer. 2019;7(1):171.","journal-title":"J Immunother Cancer"},{"issue":"656","key":"3846_CR87","doi-asserted-by":"publisher","first-page":"eabn1128","DOI":"10.1126\/scitranslmed.abn1128","volume":"14","author":"C Chen","year":"2022","unstructured":"Chen C, Jing W, Chen Y, Wang G, Abdalla M, Gao L, et al. Intracavity generation of glioma stem cell\u2013specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy. Sci Transl Med. 2022;14(656):eabn1128.","journal-title":"Sci Transl Med"},{"key":"3846_CR88","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.omtm.2022.10.010","volume":"27","author":"K Chaudhry","year":"2022","unstructured":"Chaudhry K, Geiger A, Dowlati E, Lang H, Sohai DK, Hwang EI, et al. Co-transducing B7H3 CAR-NK cells with the DNR preserves their cytolytic function against GBM in the presence of exogenous TGF-\u03b2. Mol Therapy-Methods Clin Dev. 2022;27:415\u201330.","journal-title":"Mol Therapy-Methods Clin Dev"},{"issue":"6","key":"3846_CR89","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1007\/s13402-023-00842-5","volume":"46","author":"W Liu","year":"2023","unstructured":"Liu W, Zhao Y, Liu Z, Zhang G, Wu H, Zheng X, et al. Therapeutic effects against high-grade glioblastoma mediated by engineered induced neural stem cells combined with GD2-specific CAR-NK. Cell Oncol. 2023;46(6):1747\u201362.","journal-title":"Cell Oncol"},{"issue":"3","key":"3846_CR90","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3390\/cells13030246","volume":"13","author":"A Kiefer","year":"2024","unstructured":"Kiefer A, Pr\u00fcfer M, R\u00f6der J, Pfeifer Serrahima J, Bodden M, K\u00fchnel I, et al. Dual targeting of glioblastoma cells with bispecific killer cell engagers directed to EGFR and ErbB2 (HER2) facilitates effective elimination by NKG2D-CAR-Engineered NK cells. Cells. 2024;13(3):246.","journal-title":"Cells"},{"issue":"1","key":"3846_CR91","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1038\/s41598-021-81126-6","volume":"11","author":"KS Harris","year":"2021","unstructured":"Harris KS, Shi L, Foster BM, Mobley ME, Elliott PL, Song CJ, et al. CD117\/c-kit defines a prostate CSC-like subpopulation driving progression and TKI resistance. Sci Rep. 2021;11(1):1465.","journal-title":"Sci Rep"},{"issue":"1","key":"3846_CR92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12865-014-0064-x","volume":"16","author":"Z Deng","year":"2015","unstructured":"Deng Z, Wu Y, Ma W, Zhang S, Zhang YQ. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM. BMC Immunol. 2015;16(1):1.","journal-title":"BMC Immunol"},{"issue":"3","key":"3846_CR93","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1158\/1535-7163.MCT-20-0446","volume":"20","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, He L, Sadagopan A, Ma T, Dotti G, Wang Y, et al. Targeting radiation-resistant prostate cancer stem cells by B7-H3 CAR T cells. Mol Cancer Ther. 2021;20(3):577\u201388.","journal-title":"Mol Cancer Ther"},{"issue":"18","key":"3846_CR94","doi-asserted-by":"publisher","first-page":"eadf0108","DOI":"10.1126\/sciadv.adf0108","volume":"9","author":"JS Frieling","year":"2023","unstructured":"Frieling JS, Tordesillas L, Bustos XE, Ramello MC, Bishop RT, Cianne JE, et al. \u03b3\u03b4-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer. Sci Adv. 2023;9(18):eadf0108.","journal-title":"Sci Adv"},{"issue":"1","key":"3846_CR95","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1158\/1535-7163.MCT-19-0204","volume":"19","author":"J Han","year":"2020","unstructured":"Han J, Gao F, Geng S, Ye X, Wang T, Du P, et al. Minicircle DNA-Engineered CAR T cells suppressed tumor growth in mice. Mol Cancer Ther. 2020;19(1):178\u201386.","journal-title":"Mol Cancer Ther"},{"key":"3846_CR96","doi-asserted-by":"publisher","first-page":"S440","DOI":"10.1016\/S2152-2650(22)01658-5","volume":"22","author":"G Zuccolotto","year":"2022","unstructured":"Zuccolotto G, Penna A, Fracasso G, Santa SD, Carpanese D, Montagner IM, et al. CT-227 dual CAR-Engineered NK92 cells: an Off-the-Shelf cell therapy for Cancer. Clin Lymphoma Myeloma Leuk. 2022;22:S440.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"3846_CR97","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.4049\/jimmunol.1400330","volume":"194","author":"K T\u00f6pfer","year":"2015","unstructured":"T\u00f6pfer K, Cartellieri M, Michen S, Wiedemuth R, M\u00fcller N, Lindemann D, et al. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy. J Immunol. 2015;194(7):3201\u201312.","journal-title":"J Immunol"},{"key":"3846_CR98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1749-799X-5-78","volume":"5","author":"VA Siclari","year":"2010","unstructured":"Siclari VA, Qin L. Targeting the osteosarcoma cancer stem cell. J Orthop Surg Res. 2010;5:1\u201310.","journal-title":"J Orthop Surg Res"},{"issue":"1","key":"3846_CR99","first-page":"3","volume":"4","author":"C Corro","year":"2018","unstructured":"Corro C, Moch H. Biomarker discovery for renal cancer stem cells. J Pathology: Clin Res. 2018;4(1):3\u201318.","journal-title":"J Pathology: Clin Res"},{"issue":"5","key":"3846_CR100","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1038\/s41416-022-02100-1","volume":"128","author":"Y Watanabe","year":"2023","unstructured":"Watanabe Y, Tsukahara T, Murata K, Hamada S, Kubo T, Kanaseki T, et al. Development of CAR-T cells specifically targeting cancer stem cell antigen DNAJB8 against solid tumours. Br J Cancer. 2023;128(5):886\u201395.","journal-title":"Br J Cancer"},{"issue":"7","key":"3846_CR101","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/j.apsb.2020.12.015","volume":"11","author":"J Masoumi","year":"2021","unstructured":"Masoumi J, Jafarzadeh A, Abdolalizadeh J, Khan H, Philippe J, Mirzaei H, et al. Cancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: challenges and prospects. Acta Pharm Sinica B. 2021;11(7):1721\u201339.","journal-title":"Acta Pharm Sinica B"},{"issue":"6","key":"3846_CR102","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1172\/JCI59735","volume":"122","author":"VL Battula","year":"2012","unstructured":"Battula VL, Shi Y, Evans KW, Wang RY, Spaeth EL, Jacamo RO, et al. Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. J Clin Invest. 2012;122(6):2066\u201378.","journal-title":"J Clin Invest"},{"issue":"2","key":"3846_CR103","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1158\/0008-5472.CAN-16-1911","volume":"78","author":"TT Byrd","year":"2018","unstructured":"Byrd TT, Fousek K, Pignata A, Szot C, Samaha H, Seaman S, et al. TEM8\/ANTXR1-Specific CAR T cells as a targeted therapy for Triple-Negative breast Cancer. Cancer Res. 2018;78(2):489\u2013500.","journal-title":"Cancer Res"},{"issue":"1","key":"3846_CR104","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1038\/s41598-020-59736-3","volume":"10","author":"Z Hu","year":"2020","unstructured":"Hu Z. Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer. Sci Rep. 2020;10(1):2815.","journal-title":"Sci Rep"},{"key":"3846_CR105","doi-asserted-by":"crossref","unstructured":"Sumbly V, Landry I. Understanding pancreatic cancer stem cells and their role in carcinogenesis: a narrative review. Stem Cell Invest. 2022;9.","DOI":"10.21037\/sci-2021-067"},{"issue":"5","key":"3846_CR106","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1158\/1078-0432.CCR-19-2163","volume":"27","author":"D Raj","year":"2021","unstructured":"Raj D, Nikolaidi M, Garces I, Lorizio D, Castro NM, Caiafa SG, et al. CEACAM7 is an effective target for CAR T-cell therapy of pancreatic ductal adenocarcinoma. Clin Cancer Res. 2021;27(5):1538\u201352.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3846_CR107","doi-asserted-by":"publisher","first-page":"149","DOI":"10.5115\/acb.2012.45.3.149","volume":"45","author":"H Ono","year":"2012","unstructured":"Ono H, Yanagihara K, Sakamoto H, Yoshida T, Saeki N. Prostate stem cell antigen gene is expressed in Islets of pancreas. Anat Cell Biology. 2012;45(3):149.","journal-title":"Anat Cell Biology"},{"issue":"4","key":"3846_CR108","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1053\/j.gastro.2021.12.281","volume":"162","author":"K-Y Teng","year":"2022","unstructured":"Teng K-Y, Mansour AG, Zhu Z, Li Z, Tian L, Ma S, et al. Off-the-Shelf prostate stem cell antigen\u2013directed chimeric antigen receptor natural killer cell therapy to treat pancreatic cancer. Gastroenterology. 2022;162(4):1319\u201333.","journal-title":"Gastroenterology"},{"key":"3846_CR109","doi-asserted-by":"crossref","unstructured":"Shah Z, Tian L, Li Z, Jin L, Zhang J, Li Z, et al. Human anti-PSCA CAR macrophages possess potent antitumor activity against pancreatic cancer. Cell Stem Cell. 2024;31:803\u201317.","DOI":"10.1016\/j.stem.2024.03.018"},{"issue":"5","key":"3846_CR110","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.3390\/cancers13051092","volume":"13","author":"C Hervieu","year":"2021","unstructured":"Hervieu C, Christou N, Battu S, Mathonnet M. The role of cancer stem cells in colorectal cancer: from the basics to novel clinical trials. Cancers. 2021;13(5):1092.","journal-title":"Cancers"},{"key":"3846_CR111","doi-asserted-by":"publisher","unstructured":"Xu X. Inducible secreting TLR5 agonist CBLB502 enhances antitumor activity of CAR133-NK92 cells for colorectal cancer. 2022. https:\/\/doi.org\/10.21203\/rs.3.rs-1227221\/v1.","DOI":"10.21203\/rs.3.rs-1227221\/v1"},{"key":"3846_CR112","doi-asserted-by":"publisher","first-page":"S880","DOI":"10.1016\/j.annonc.2022.07.863","volume":"33","author":"W Fang","year":"2022","unstructured":"Fang W, Luo T, Lu Z, Zhang H, Tong C, Wang S, et al. 737MO EpCAM-targeted CAR-T cell therapy in patients with advanced colorectal and gastric cancers. Ann Oncol. 2022;33:S880\u20131.","journal-title":"Ann Oncol"},{"issue":"1","key":"3846_CR113","first-page":"4263520","volume":"2018","author":"Q Zhang","year":"2018","unstructured":"Zhang Q, Zhang H, Ding J, Liu H, Li H, Li H, et al. Combination therapy with EpCAM-CAR-NK-92 cells and regorafenib against human colorectal cancer models. J Immunol Res. 2018;2018(1):4263520.","journal-title":"J Immunol Res"},{"issue":"22","key":"3846_CR114","doi-asserted-by":"publisher","first-page":"6629","DOI":"10.7150\/jca.62123","volume":"12","author":"L Liu","year":"2021","unstructured":"Liu L, Liu Y, Xia Y, Wang G, Zhang X, Zhang H, et al. Synergistic killing effects of PD-L1-CAR T cells and colorectal cancer stem cell-dendritic cell vaccine-sensitized T cells in ALDH1-positive colorectal cancer stem cells. J Cancer. 2021;12(22):6629.","journal-title":"J Cancer"},{"key":"3846_CR115","doi-asserted-by":"publisher","first-page":"101575","DOI":"10.1016\/j.tranon.2022.101575","volume":"27","author":"S He","year":"2023","unstructured":"He S, Li S, Guo J, Zeng X, Liang D, Zhu Y, et al. CD166-specific CAR-T cells potently target colorectal cancer cells. Transl Oncol. 2023;27:101575.","journal-title":"Transl Oncol"},{"issue":"7Supplement","key":"3846_CR116","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.1158\/1538-7445.AM2023-4085","volume":"83","author":"V Bandara","year":"2023","unstructured":"Bandara V, Gundsambuu B, Napoli S, Mills S, Thompson E, Tan L, et al. Development and in vitro validation of an LGR-5 targeting CAR-T against colorectal cancer. Cancer Res. 2023;83(7Supplement):4085.","journal-title":"Cancer Res"},{"issue":"7Supplement","key":"3846_CR117","doi-asserted-by":"publisher","first-page":"5545","DOI":"10.1158\/1538-7445.AM2023-5545","volume":"83","author":"EJ Thompson","year":"2023","unstructured":"Thompson EJ, Bandara V, Gundsambuu B, Napoli S, Mills S, Foeng J, et al. Assessing LGR5 expression levels on colorectal cancer tissue samples for use in LGR5-targeting CAR-T cell therapy clinical trial. Cancer Res. 2023;83(7Supplement):5545.","journal-title":"Cancer Res"},{"key":"3846_CR118","doi-asserted-by":"publisher","first-page":"803974","DOI":"10.3389\/fonc.2021.803974","volume":"11","author":"Y Yang","year":"2022","unstructured":"Yang Y, Meng W-J, Wang Z-Q. Cancer stem cells and the tumor microenvironment in gastric cancer. Front Oncol. 2022;11:803974.","journal-title":"Front Oncol"},{"issue":"1","key":"3846_CR119","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12935-022-02471-8","volume":"22","author":"F Sun","year":"2022","unstructured":"Sun F, Yu X, Ju R, Wang Z, Wang Y. Antitumor responses in gastric cancer by targeting B7H3 via chimeric antigen receptor T cells. Cancer Cell Int. 2022;22(1):50.","journal-title":"Cancer Cell Int"},{"issue":"10","key":"3846_CR120","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s13238-017-0384-8","volume":"9","author":"Y Song","year":"2018","unstructured":"Song Y, Tong C, Wang Y, Gao Y, Dai H, Guo Y, et al. Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo. Protein Cell. 2018;9(10):867\u201378.","journal-title":"Protein Cell"},{"issue":"10","key":"3846_CR121","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1007\/s00262-021-02891-x","volume":"70","author":"Y Han","year":"2021","unstructured":"Han Y, Sun B, Cai H, Xuan Y. Simultaneously target of normal and stem cells-like gastric cancer cells via cisplatin and anti-CD133 CAR-T combination therapy. Cancer Immunol Immunother. 2021;70(10):2795\u2013803.","journal-title":"Cancer Immunol Immunother"},{"key":"3846_CR122","doi-asserted-by":"publisher","first-page":"873994","DOI":"10.3389\/fonc.2022.873994","volume":"12","author":"Y Zheng","year":"2022","unstructured":"Zheng Y, Wang L, Yin L, Yao Z, Tong R, Xue J, et al. Lung cancer stem cell markers as therapeutic targets: an update on signaling pathways and therapies. Front Oncol. 2022;12:873994.","journal-title":"Front Oncol"},{"issue":"3","key":"3846_CR123","doi-asserted-by":"publisher","first-page":"e1284722","DOI":"10.1080\/2162402X.2017.1284722","volume":"6","author":"X Wei","year":"2017","unstructured":"Wei X, Lai Y, Li J, Qin L, Xu Y, Zhao R, et al. PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells. Oncoimmunology. 2017;6(3):e1284722.","journal-title":"Oncoimmunology"},{"issue":"8","key":"3846_CR124","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41389-020-00257-z","volume":"9","author":"M Liu","year":"2020","unstructured":"Liu M, Wang X, Li W, Yu X, Flores-Villanueva P, Xu-Monette ZY, et al. Targeting PD-L1 in non-small cell lung cancer using CAR T cells. Oncogenesis. 2020;9(8):72.","journal-title":"Oncogenesis"},{"issue":"1","key":"3846_CR125","doi-asserted-by":"publisher","first-page":"564","DOI":"10.3390\/ijms25010564","volume":"25","author":"S Wang","year":"2024","unstructured":"Wang S, Wei W, Yuan Y, Guo J, Liang D, Zhao X. Cell-surface grp78-targeted chimeric antigen receptor T cells eliminate lung cancer tumor xenografts. Int J Mol Sci. 2024;25(1):564.","journal-title":"Int J Mol Sci"},{"key":"3846_CR126","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3389\/fimmu.2017.00404","volume":"8","author":"L Liu","year":"2017","unstructured":"Liu L, Zhang L, Yang L, Li H, Li R, Yu J, et al. Anti-CD47 antibody as a targeted therapeutic agent for human lung cancer and cancer stem cells. Front Immunol. 2017;8:404.","journal-title":"Front Immunol"},{"issue":"1","key":"3846_CR127","first-page":"5575260","volume":"2021","author":"HT La","year":"2021","unstructured":"La HT, Tran DBT, Tran HM, Nguyen LT. Third-generation anti-CD47-specific CAR-T cells effectively kill cancer cells and reduce the genes expression in lung cancer cell metastasis. J Immunol Res. 2021;2021(1):5575260.","journal-title":"J Immunol Res"},{"key":"3846_CR128","doi-asserted-by":"publisher","first-page":"215697","DOI":"10.1016\/j.canlet.2022.215697","volume":"538","author":"S Taromi","year":"2022","unstructured":"Taromi S, Firat E, Simonis A, Braun LM, Apostolova P, Elze M, et al. Enhanced AC133-specific CAR T cell therapy induces durable remissions in mice with metastatic small cell lung cancer. Cancer Lett. 2022;538:215697.","journal-title":"Cancer Lett"},{"key":"3846_CR129","doi-asserted-by":"publisher","first-page":"665970","DOI":"10.3389\/fimmu.2021.665970","volume":"12","author":"Y Jie","year":"2021","unstructured":"Jie Y, Liu G, Feng L, Li Y, E M, Wu L, et al. PTK7-targeting CAR T-cells for the treatment of lung cancer and other malignancies. Front Immunol. 2021;12:665970.","journal-title":"Front Immunol"},{"issue":"12","key":"3846_CR130","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00262-024-03837-9","volume":"73","author":"J Blobner","year":"2024","unstructured":"Blobner J, Dengler L, Eberle C, Herold JJ, Xu T, Beck A, et al. PD-1 Blockade does not improve efficacy of EpCAM-directed CAR T-cell in lung cancer brain metastasis. Cancer Immunol Immunother. 2024;73(12):255.","journal-title":"Cancer Immunol Immunother"},{"key":"3846_CR131","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3389\/fimmu.2020.00099","volume":"11","author":"S Porcellini","year":"2020","unstructured":"Porcellini S, Asperti C, Corna S, Cicoria E, Valtolina V, Stornaiuolo A, et al. CAR T cells redirected to CD44v6 control tumor growth in lung and ovary adenocarcinoma bearing mice. Front Immunol. 2020;11:99.","journal-title":"Front Immunol"},{"key":"3846_CR132","doi-asserted-by":"publisher","first-page":"102701","DOI":"10.1016\/j.scr.2022.102701","volume":"60","author":"P Xia","year":"2022","unstructured":"Xia P, Liu D-H. Cancer stem cell markers for liver cancer and pancreatic cancer. Stem Cell Res. 2022;60:102701.","journal-title":"Stem Cell Res"},{"issue":"1","key":"3846_CR133","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s12916-023-03016-0","volume":"21","author":"C Yang","year":"2023","unstructured":"Yang C, You J, Pan Q, Tang Y, Cai L, Huang Y, et al. Targeted delivery of a PD-1-blocking ScFv by CD133-specific CAR-T cells using nonviral sleeping beauty transposition shows enhanced antitumour efficacy for advanced hepatocellular carcinoma. BMC Med. 2023;21(1):327.","journal-title":"BMC Med"},{"issue":"1","key":"3846_CR134","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1186\/s12885-022-09861-1","volume":"22","author":"H Wang","year":"2022","unstructured":"Wang H, Wang X, Ye X, Ju Y, Cao N, Wang S, et al. Nonviral mcDNA-mediated bispecific CAR T cells kill tumor cells in an experimental mouse model of hepatocellular carcinoma. BMC Cancer. 2022;22(1):814.","journal-title":"BMC Cancer"},{"issue":"7","key":"3846_CR135","doi-asserted-by":"publisher","first-page":"e1440169","DOI":"10.1080\/2162402X.2018.1440169","volume":"7","author":"Y Wang","year":"2018","unstructured":"Wang Y, Chen M, Wu Z, Tong C, Dai H, Guo Y, et al. CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial. Oncoimmunology. 2018;7(7):e1440169.","journal-title":"Oncoimmunology"},{"issue":"1","key":"3846_CR136","doi-asserted-by":"publisher","first-page":"1846926","DOI":"10.1080\/2162402X.2020.1846926","volume":"9","author":"H Dai","year":"2020","unstructured":"Dai H, Tong C, Shi D, Chen M, Guo Y, Chen D, et al. Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial. Oncoimmunology. 2020;9(1):1846926.","journal-title":"Oncoimmunology"},{"key":"3846_CR137","doi-asserted-by":"crossref","unstructured":"Wang H, Ye X, Ju Y, Cai Z, Wang X, Du P, et al. Minicircle DNA-mediated CAR T cells targeting CD44 suppressed hepatocellular carcinoma both in vitro and in vivo. Onco Targets Ther. 2020;13:3703\u201316.","DOI":"10.2147\/OTT.S247836"},{"issue":"2","key":"3846_CR138","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3892\/ijo.2020.5074","volume":"57","author":"NA McGrath","year":"2020","unstructured":"McGrath NA, Fu J, Gu SZ, Xie C. Targeting cancer stem cells in cholangiocarcinoma. Int J Oncol. 2020;57(2):397\u2013408.","journal-title":"Int J Oncol"},{"key":"3846_CR139","doi-asserted-by":"publisher","first-page":"107069","DOI":"10.1016\/j.intimp.2020.107069","volume":"89","author":"T Sangsuwannukul","year":"2020","unstructured":"Sangsuwannukul T, Supimon K, Sujjitjoon J, Phanthaphol N, Chieochansin T, Poungvarin N, et al. Anti-tumour effect of the fourth-generation chimeric antigen receptor T cells targeting CD133 against cholangiocarcinoma cells. Int Immunopharmacol. 2020;89:107069.","journal-title":"Int Immunopharmacol"},{"issue":"7Supplement","key":"3846_CR140","doi-asserted-by":"publisher","first-page":"4105","DOI":"10.1158\/1538-7445.AM2023-4105","volume":"83","author":"T Sangsuwannukul","year":"2023","unstructured":"Sangsuwannukul T, Supimon K, Chieochansin T, Choomee K, Sujjitjoon J, Junking M, et al. Improvement of CD133-specific chimeric antigen receptor T cells by secreting anti-PD-L1 single-chain variable fragment against cholangiocarcinoma. Cancer Res. 2023;83(7Supplement):4105.","journal-title":"Cancer Res"},{"issue":"6","key":"3846_CR141","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ol.2022.13585","volume":"24","author":"P Kr\u00f3lewska-Daszczy\u0144ska","year":"2022","unstructured":"Kr\u00f3lewska-Daszczy\u0144ska P, Wendlocha D, Smycz-Kuba\u0144ska M, St\u0119pie\u0144 S, Mielczarek-Palacz A. Cancer stem cells markers in ovarian cancer: clinical and therapeutic significance. Oncol Lett. 2022;24(6):1\u201310.","journal-title":"Oncol Lett"},{"issue":"2","key":"3846_CR142","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1292\/jvms.20-0455","volume":"83","author":"J Fu","year":"2021","unstructured":"Fu J, Shang Y, Qian Z, Hou J, Yan F, Liu G, et al. Chimeric antigen receptor-T (CAR-T) cells targeting epithelial cell adhesion molecule (EpCAM) can inhibit tumor growth in ovarian cancer mouse model. J Vet Med Sci. 2021;83(2):241\u20137.","journal-title":"J Vet Med Sci"},{"issue":"3","key":"3846_CR143","doi-asserted-by":"publisher","first-page":"660","DOI":"10.3390\/ijms20030660","volume":"20","author":"R Klapdor","year":"2019","unstructured":"Klapdor R, Wang S, Morgan M, D\u00f6rk T, Hacker U, Hillemanns P, et al. Characterization of a novel third-generation anti-CD24-CAR against ovarian cancer. Int J Mol Sci. 2019;20(3):660.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"3846_CR144","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1089\/hum.2017.168","volume":"28","author":"R Klapdor","year":"2017","unstructured":"Klapdor R, Wang S, Hacker U, B\u00fcning H, Morgan M, D\u00f6rk T, et al. Improved killing of ovarian cancer stem cells by combining a novel chimeric antigen receptor\u2013based immunotherapy and chemotherapy. Hum Gene Ther. 2017;28(10):886\u201396.","journal-title":"Hum Gene Ther"},{"issue":"10","key":"3846_CR145","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.3390\/biomedicines9101339","volume":"9","author":"R Klapdor","year":"2021","unstructured":"Klapdor R, Wang S, Morgan MA, Zimmermann K, Hachenberg J, B\u00fcning H, et al. NK cell-mediated eradication of ovarian cancer cells with a novel chimeric antigen receptor directed against CD44. Biomedicines. 2021;9(10):1339.","journal-title":"Biomedicines"},{"key":"3846_CR146","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.3389\/fonc.2019.01358","volume":"9","author":"S Yao","year":"2019","unstructured":"Yao S, Jianlin C, Yarong L, Botao L, Qinghan W, Hongliang F, et al. Donor-derived CD123-targeted CAR T cell serves as a RIC regimen for haploidentical transplantation in a patient with FUS-ERG\u2009+\u2009AML. Front Oncol. 2019;9:1358.","journal-title":"Front Oncol"},{"issue":"Supplement 1","key":"3846_CR147","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1182\/blood-2022-168877","volume":"140","author":"G Ehninger","year":"2022","unstructured":"Ehninger G, Kraus S, Sala E, Metzelder SK, Vucinic V, Fiedler W, et al. Phase 1 dose escalation study of the rapidly switchable universal CAR-T therapy unicar-T-CD123 in relapsed\/refractory AML. Blood. 2022;140(Supplement 1):2367\u20138.","journal-title":"Blood"},{"issue":"Supplement 1","key":"3846_CR148","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1182\/blood-2022-169928","volume":"140","author":"DA Sallman","year":"2022","unstructured":"Sallman DA, DeAngelo DJ, Pemmaraju N, Dinner S, Gill S, Olin RL, et al. Ameli-01: a phase I trial of UCART123v1. 2, an anti-CD123 allogeneic CAR-T cell product, in adult patients with relapsed or refractory (R\/R) CD123\u2009+\u2009acute myeloid leukemia (AML). Blood. 2022;140(Supplement 1):2371\u20133.","journal-title":"Blood"},{"key":"3846_CR149","first-page":"1359","volume":"130","author":"KD Cummins","year":"2017","unstructured":"Cummins KD, Frey N, Nelson AM, Schmidt A, Luger S, Isaacs RE, et al. Treating relapsed\/refractory (RR) AML with biodegradable anti-CD123 CAR modified T cells. Blood. 2017;130:1359.","journal-title":"Blood"},{"key":"3846_CR150","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.1182\/blood-2023-177867","volume":"142","author":"M Wermke","year":"2023","unstructured":"Wermke M, Metzelder S, Kraus S, Sala E, Vucinic V, Fiedler W, et al. Updated results from a phase I dose escalation study of the rapidly-switchable universal CAR-T therapy uniCAR-T-CD123 in relapsed\/refractory AML. Blood. 2023;142:3465.","journal-title":"Blood"},{"issue":"11","key":"3846_CR151","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1038\/s41375-022-01703-0","volume":"36","author":"H Zhang","year":"2022","unstructured":"Zhang H, Bu C, Peng Z, Li G, Zhou Z, Ding W, et al. Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis. Leukemia. 2022;36(11):2596\u2013604.","journal-title":"Leukemia"},{"issue":"1","key":"3846_CR152","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1186\/s12967-024-05705-7","volume":"22","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Bai X, Guo S, Zhang X, Liu J, Zhao M, et al. Efficacy and safety of CAR-T therapy targeting CLL1 in patients with extramedullary diseases of acute myeloid leukemia. J Translational Med. 2024;22(1):888.","journal-title":"J Translational Med"},{"issue":"3","key":"3846_CR153","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s00277-024-05617-y","volume":"103","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Zhang X, Zhang M, Guo R, Zhang Y, Pu Y, et al. Modified EASIX scores predict severe CRS\/ICANS in patients with acute myeloid leukemia following CLL1 CAR-T cell therapy. Ann Hematol. 2024;103(3):969\u201380.","journal-title":"Ann Hematol"},{"key":"3846_CR154","doi-asserted-by":"publisher","first-page":"1389227","DOI":"10.3389\/fimmu.2024.1389227","volume":"15","author":"X Miao","year":"2024","unstructured":"Miao X, Shuai Y, Han Y, Zhang N, Liu Y, Yao H, et al. Case report: Donor-derived CLL-1 chimeric antigen receptor T-cell therapy for relapsed\/refractory acute myeloid leukemia bridging to allogeneic hematopoietic stem cell transplantation after remission. Front Immunol. 2024;15:1389227.","journal-title":"Front Immunol"},{"issue":"13","key":"3846_CR155","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1158\/1078-0432.CCR-20-4543","volume":"27","author":"H Zhang","year":"2021","unstructured":"Zhang H, Wang P, Li Z, He Y, Gan W, Jiang H. Anti-CLL1 chimeric antigen receptor T-cell therapy in children with relapsed\/refractory acute myeloid leukemia. Clin Cancer Res. 2021;27(13):3549\u201355.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"3846_CR156","doi-asserted-by":"publisher","first-page":"9655","DOI":"10.1002\/cam4.5916","volume":"12","author":"K Pei","year":"2023","unstructured":"Pei K, Xu H, Wang P, Gan W, Hu Z, Su X, et al. Anti-CLL1-based CAR T-cells with 4-1-BB or CD28\/CD27 stimulatory domains in treating childhood refractory\/relapsed acute myeloid leukemia. Cancer Med. 2023;12(8):9655\u201361.","journal-title":"Cancer Med"},{"key":"3846_CR157","unstructured":"Liu F, Zhang H, Sun L, Li Y, Zhang S, He G, et al. editors. First-in-human CLL1-CD33 compound CAR (cCAR) T cell therapy in relapsed and refractory acute myeloid leukemia. Proceedings of the 25th EHA Annual Congress, Frankfurt, Germany; 2020."},{"issue":"11","key":"3846_CR158","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1038\/mt.2013.154","volume":"21","author":"DS Ritchie","year":"2013","unstructured":"Ritchie DS, Neeson PJ, Khot A, Peinert S, Tai T, Tainton K, et al. Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther. 2013;21(11):2122\u20139.","journal-title":"Mol Ther"},{"key":"3846_CR159","doi-asserted-by":"crossref","unstructured":"Pan J, Zuo S, Li C, Ling Z, Xu J, Duan J, et al. Phase I study of functionally enhanced CD33 CAR T cells in patients with relapsed or refractory acute myeloid leukemia. American Society of Clinical Oncology; 2024.","DOI":"10.1200\/JCO.2024.42.16_suppl.6518"},{"issue":"Supplement 1","key":"3846_CR160","doi-asserted-by":"publisher","first-page":"4600","DOI":"10.1182\/blood-2022-168891","volume":"140","author":"L Shelikhova","year":"2022","unstructured":"Shelikhova L, Rakhteenko A, Molostova O, Kurnikova E, Ukrainskaya V, Muzalevsky Y, et al. Allogeneic donor-derived myeloid antigen directed CAR-T cells-for relapsed\/refractory acute myeloid leukemia in children after allogeneic hematopoietic stem cell transplantation: report of three cases. Blood. 2022;140(Supplement 1):4600\u20131.","journal-title":"Blood"},{"issue":"6","key":"3846_CR161","first-page":"1083","volume":"8","author":"X Tang","year":"2018","unstructured":"Tang X, Yang L, Li Z, Nalin AP, Dai H, Xu T, et al. First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am J cancer Res. 2018;8(6):1083.","journal-title":"Am J cancer Res"},{"issue":"Supplement 1","key":"3846_CR162","doi-asserted-by":"publisher","first-page":"7450","DOI":"10.1182\/blood-2022-170712","volume":"140","author":"R Huang","year":"2022","unstructured":"Huang R, Wen Q, Wang X, Yan H, Ma Y, Mai-Hong W, et al. Off-the-Shelf CD33 CAR-NK cell therapy for relapse\/refractory AML: first-in-human, phase I trial. Blood. 2022;140(Supplement 1):7450\u20131.","journal-title":"Blood"},{"key":"3846_CR163","doi-asserted-by":"crossref","unstructured":"Bagley SJ, Binder ZA, Lamrani L, Marinari E, Desai AS, Nasrallah MP, et al. Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial. Nat Cancer. 2024;5:517\u201331. 1\u201315.","DOI":"10.1038\/s43018-023-00709-6"},{"issue":"5","key":"3846_CR164","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","volume":"30","author":"SJ Bagley","year":"2024","unstructured":"Bagley SJ, Logun M, Fraietta JA, Wang X, Desai AS, Bagley LJ, et al. Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results. Nat Med. 2024;30(5):1320\u20139.","journal-title":"Nat Med"},{"issue":"14","key":"3846_CR165","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","volume":"390","author":"BD Choi","year":"2024","unstructured":"Choi BD, Gerstner ER, Frigault MJ, Leick MB, Mount CW, Balaj L, et al. Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma. N Engl J Med. 2024;390(14):1290\u20138.","journal-title":"N Engl J Med"},{"key":"3846_CR166","doi-asserted-by":"crossref","unstructured":"Dorff TB, Blanchard MS, Adkins LN, Luebbert L, Leggett N, Shishido SN, et al. PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med. 2024;30:1636\u201344. 1\u20139.","DOI":"10.1038\/s41591-024-02979-8"},{"issue":"48","key":"3846_CR167","doi-asserted-by":"publisher","first-page":"eadg9721","DOI":"10.1126\/sciadv.adg9721","volume":"9","author":"D Li","year":"2023","unstructured":"Li D, Guo X, Yang K, Yang Y, Zhou W, Huang Y, et al. EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors. Sci Adv. 2023;9(48):eadg9721.","journal-title":"Sci Adv"},{"key":"3846_CR168","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-016-0378-7","volume":"10","author":"K-c Feng","year":"2017","unstructured":"Feng K-c, Guo Y-l, Liu Y, Dai H-r, Wang Y, Lv H-y, et al. Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma. J Hematol Oncol. 2017;10:1\u201311.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"3846_CR169","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24(6):739\u201348.","journal-title":"Nat Med"},{"issue":"1","key":"3846_CR170","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","volume":"32","author":"M-L Schubert","year":"2021","unstructured":"Schubert M-L, Schmitt M, Wang L, Ramos C, Jordan K, M\u00fcller-Tidow C, et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 2021;32(1):34\u201348.","journal-title":"Ann Oncol"},{"issue":"1","key":"3846_CR171","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/diseases9010020","volume":"9","author":"EA Burns","year":"2021","unstructured":"Burns EA, Gentille C, Trachtenberg B, Pingali SR, Anand K. Cardiotoxicity associated with anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy: recognition, risk factors, and management. Diseases. 2021;9(1):20.","journal-title":"Diseases"},{"key":"3846_CR172","doi-asserted-by":"crossref","unstructured":"Hanna KS, Kaur H, Alazzeh MS, Thandavaram A, Channar A, Purohit A et al. Cardiotoxicity associated with chimeric antigen receptor (CAR)-T cell therapy for hematologic malignancies: A systematic review. Cureus. 2022;14(8).","DOI":"10.7759\/cureus.28162"},{"issue":"12","key":"3846_CR173","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust J, Hay KA, Hanafi L-A, Li D, Myerson D, Gonzalez-Cuyar LF, et al. Endothelial activation and blood\u2013brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7(12):1404\u201319.","journal-title":"Cancer Discov"},{"issue":"20","key":"3846_CR174","first-page":"2212","volume":"133","author":"P Karschnia","year":"2019","unstructured":"Karschnia P, Jordan JT, Forst DA, Arrillaga-Romany IC, Batchelor TT, Baehring JM, et al. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood J Am Soc Hematol. 2019;133(20):2212\u201321.","journal-title":"Blood J Am Soc Hematol"},{"issue":"1","key":"3846_CR175","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","volume":"20","author":"CL Flugel","year":"2023","unstructured":"Flugel CL, Majzner RG, Krenciute G, Dotti G, Riddell SR, Wagner DL, et al. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Reviews Clin Oncol. 2023;20(1):49\u201362.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"6","key":"3846_CR176","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.3390\/ijms20061283","volume":"20","author":"M-R Benmebarek","year":"2019","unstructured":"Benmebarek M-R, Karches CH, Cadilha BL, Lesch S, Endres S, Kobold S. Killing mechanisms of chimeric antigen receptor (CAR) T cells. Int J Mol Sci. 2019;20(6):1283.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"3846_CR177","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1007\/s12015-024-10786-4","volume":"20","author":"LE Rabie","year":"2024","unstructured":"Rabie LE, Mohran AA, Gaber KA, Ali NM, Abd El Naby AM, Ghoniem EA, et al. Beyond conventional treatments: exploring CAR-T cell therapy for cancer stem cell eradication. Stem Cell Reviews Rep. 2024;20(8):2001\u201315.","journal-title":"Stem Cell Reviews Rep"},{"issue":"2","key":"3846_CR178","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/ejh.14101","volume":"112","author":"A Mishra","year":"2024","unstructured":"Mishra A, Maiti R, Mohan P, Gupta P. Antigen loss following CAR-T cell therapy: mechanisms, implications, and potential solutions. Eur J Haematol. 2024;112(2):211\u201322.","journal-title":"Eur J Haematol"},{"key":"3846_CR179","doi-asserted-by":"publisher","first-page":"813832","DOI":"10.3389\/fimmu.2021.813832","volume":"12","author":"VM Qin","year":"2022","unstructured":"Qin VM, Haynes NM, D\u2019Souza C, Neeson PJ, Zhu JJ. CAR-T plus radiotherapy: a promising combination for immunosuppressive tumors. Front Immunol. 2022;12:813832.","journal-title":"Front Immunol"},{"key":"3846_CR180","doi-asserted-by":"publisher","first-page":"107753","DOI":"10.1016\/j.pharmthera.2020.107753","volume":"221","author":"Y Xiao","year":"2021","unstructured":"Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther. 2021;221:107753.","journal-title":"Pharmacol Ther"},{"issue":"14","key":"3846_CR181","doi-asserted-by":"publisher","first-page":"6273","DOI":"10.7150\/thno.76854","volume":"12","author":"Z Liu","year":"2022","unstructured":"Liu Z, Zhou Z, Dang Q, Xu H, Lv J, Li H, et al. Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy. Theranostics. 2022;12(14):6273.","journal-title":"Theranostics"},{"issue":"1","key":"3846_CR182","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3390\/cancers16010039","volume":"16","author":"A Majumder","year":"2023","unstructured":"Majumder A. Evolving CAR-T-Cell therapy for Cancer treatment: from scientific discovery to cures. Cancers. 2023;16(1):39.","journal-title":"Cancers"},{"issue":"12","key":"3846_CR183","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1038\/s41422-022-00745-4","volume":"32","author":"S Castelli","year":"2022","unstructured":"Castelli S, Young RM, June CH. Off-the-shelf CAR T cells to treat cancer. Cell Res. 2022;32(12):1036\u20137.","journal-title":"Cell Res"},{"issue":"7949","key":"3846_CR184","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","volume":"614","author":"L Labanieh","year":"2023","unstructured":"Labanieh L, Mackall CL. CAR immune cells: design principles, resistance and the next generation. Nature. 2023;614(7949):635\u201348.","journal-title":"Nature"},{"key":"3846_CR185","doi-asserted-by":"publisher","first-page":"1407992","DOI":"10.3389\/fimmu.2024.1407992","volume":"15","author":"AM Alviano","year":"2024","unstructured":"Alviano AM, Biondi M, Grassenis E, Biondi A, Serafini M, Tettamanti S. Fully equipped cars to address tumor heterogeneity, enhance safety, and improve the functionality of cellular immunotherapies. Front Immunol. 2024;15:1407992.","journal-title":"Front Immunol"},{"key":"3846_CR186","doi-asserted-by":"crossref","unstructured":"Grauwet K, Berger T, Kann MC, Silva H, Larson R, Leick MB et al. Stealth transgenes enable CAR-T cells to evade host immune responses. J Immunother Cancer. 2024;12(5).","DOI":"10.1136\/jitc-2023-008417"},{"issue":"2","key":"3846_CR187","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41591-021-01621-1","volume":"28","author":"J Mansilla-Soto","year":"2022","unstructured":"Mansilla-Soto J, Eyquem J, Haubner S, Hamieh M, Feucht J, Paillon N, et al. HLA-independent T cell receptors for targeting tumors with low antigen density. Nat Med. 2022;28(2):345\u201352.","journal-title":"Nat Med"},{"key":"3846_CR188","doi-asserted-by":"publisher","first-page":"1124272","DOI":"10.3389\/fonc.2023.1124272","volume":"13","author":"M Potez","year":"2023","unstructured":"Potez M, Snedal S, She C, Kim J, Thorner K, Tran TH, et al. Use of phage display biopanning as a tool to design CAR-T cells against glioma stem cells. Front Oncol. 2023;13:1124272.","journal-title":"Front Oncol"},{"key":"3846_CR189","doi-asserted-by":"crossref","unstructured":"Li G, Wu X, Chan IH, Trager JB. A combination of CAR-NK and CAR-T cells results in rapid and persistent anti-tumor efficacy while reducing CAR-T cell mediated cytokine release and T-cell proliferation. American Association for Cancer Research; 2020.","DOI":"10.1158\/1538-7445.AM2020-4235"},{"issue":"22","key":"3846_CR190","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.3390\/cells11223692","volume":"11","author":"M Liu","year":"2022","unstructured":"Liu M, Liu J, Liang Z, Dai K, Gan J, Wang Q, et al. CAR-macrophages and CAR-T cells synergistically kill tumor cells in vitro. Cells. 2022;11(22):3692.","journal-title":"Cells"},{"issue":"3","key":"3846_CR191","first-page":"880","volume":"5","author":"H Liu","year":"2015","unstructured":"Liu H, Lv L, Yang K. Chemotherapy targeting cancer stem cells. Am J cancer Res. 2015;5(3):880.","journal-title":"Am J cancer Res"},{"issue":"1","key":"3846_CR192","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","volume":"22","author":"KM Maalej","year":"2023","unstructured":"Maalej KM, Merhi M, Inchakalody VP, Mestiri S, Alam M, Maccalli C, et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol Cancer. 2023;22(1):20.","journal-title":"Mol Cancer"},{"key":"3846_CR193","doi-asserted-by":"publisher","first-page":"1298683","DOI":"10.3389\/fimmu.2023.1298683","volume":"14","author":"J He","year":"2023","unstructured":"He J, Yan Y, Zhang J, Wei Z, Li H, Xing L. Synergistic treatment strategy: combining CAR-NK cell therapy and radiotherapy to combat solid tumors. Front Immunol. 2023;14:1298683.","journal-title":"Front Immunol"},{"issue":"5","key":"3846_CR194","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022;29(5):3044\u201360.","journal-title":"Curr Oncol"},{"key":"3846_CR195","doi-asserted-by":"crossref","unstructured":"Hatae R, Kyewalabye K, Yamamichi A, Chen T, Phyu S, Chuntova P et al. Enhancing CAR-T cell metabolism to overcome hypoxic conditions in the brain tumor microenvironment. JCI Insight. 2024;9(7).","DOI":"10.1172\/jci.insight.177141"},{"key":"3846_CR196","doi-asserted-by":"crossref","unstructured":"Dong X, Ren J, Amoozgar Z, Lee S, Datta M, Roberge S et al. Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice. J Immunother Cancer. 2023;11(3).","DOI":"10.1136\/jitc-2022-005583"},{"issue":"1","key":"3846_CR197","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41392-020-0110-5","volume":"5","author":"L Yang","year":"2020","unstructured":"Yang L, Shi P, Zhao G, Xu J, Peng W, Zhang J, et al. Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target Ther. 2020;5(1):8.","journal-title":"Signal Transduct Target Ther"},{"key":"3846_CR198","doi-asserted-by":"publisher","first-page":"650772","DOI":"10.3389\/fcell.2021.650772","volume":"9","author":"V Kumar","year":"2021","unstructured":"Kumar V, Vashishta M, Kong L, Wu X, Lu JJ, Guha C, et al. The role of notch, hedgehog, and Wnt signaling pathways in the resistance of tumors to anticancer therapies. Front Cell Dev Biol. 2021;9:650772.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"3846_CR199","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41392-024-01828-x","volume":"9","author":"Q Shi","year":"2024","unstructured":"Shi Q, Xue C, Zeng Y, Yuan X, Chu Q, Jiang S, et al. Notch signaling pathway in cancer: from mechanistic insights to targeted therapies. Signal Transduct Target Ther. 2024;9(1):128.","journal-title":"Signal Transduct Target Ther"},{"key":"3846_CR200","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3389\/fonc.2018.00203","volume":"8","author":"V Snyder","year":"2018","unstructured":"Snyder V, Reed-Newman TC, Arnold L, Thomas SM, Anant S. Cancer stem cell metabolism and potential therapeutic targets. Front Oncol. 2018;8:203.","journal-title":"Front Oncol"},{"issue":"1","key":"3846_CR201","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s13287-024-03783-4","volume":"15","author":"F Sani","year":"2024","unstructured":"Sani F, Shojaei S, Tabatabaei SA, Khorraminejad-Shirazi M, Latifi M, Sani M, et al. CAR-T cell-derived exosomes: a new perspective for cancer therapy. Stem Cell Res Ther. 2024;15(1):174.","journal-title":"Stem Cell Res Ther"},{"issue":"11","key":"3846_CR202","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1158\/0008-5472.CAN-22-3864","volume":"83","author":"M Chakravarti","year":"2023","unstructured":"Chakravarti M, Dhar S, Bera S, Sinha A, Roy K, Sarkar A, et al. Terminally exhausted CD8\u2009+\u2009T cells resistant to PD-1 Blockade promote generation and maintenance of aggressive cancer stem cells. Cancer Res. 2023;83(11):1815\u201333.","journal-title":"Cancer Res"},{"issue":"42","key":"3846_CR203","doi-asserted-by":"publisher","first-page":"44179","DOI":"10.18632\/oncotarget.6175","volume":"6","author":"X-J Tang","year":"2015","unstructured":"Tang X-J, Sun X-Y, Huang K-M, Zhang L, Yang Z-S, Zou D-D, et al. Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapy. Oncotarget. 2015;6(42):44179.","journal-title":"Oncotarget"},{"issue":"1","key":"3846_CR204","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s12276-023-01132-8","volume":"56","author":"I Jung","year":"2024","unstructured":"Jung I, Shin S, Baek M-C, Yea K. Modification of immune cell-derived exosomes for enhanced cancer immunotherapy: current advances and therapeutic applications. Exp Mol Med. 2024;56(1):19\u201331.","journal-title":"Exp Mol Med"},{"issue":"6","key":"3846_CR205","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/s41417-021-00352-2","volume":"29","author":"Y Enomoto","year":"2022","unstructured":"Enomoto Y, Li P, Jenkins LM, Anastasakis D, Lyons GC, Hafner M, et al. Cytokine-enhanced cytolytic activity of exosomes from NK cells. Cancer Gene Ther. 2022;29(6):734\u201349.","journal-title":"Cancer Gene Ther"},{"key":"3846_CR206","doi-asserted-by":"publisher","first-page":"1354825","DOI":"10.3389\/fimmu.2024.1354825","volume":"15","author":"R Tao","year":"2024","unstructured":"Tao R, Han X, Bai X, Yu J, Ma Y, Chen W, et al. Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR\/Cas9 gene editing technology. Front Immunol. 2024;15:1354825.","journal-title":"Front Immunol"},{"issue":"15","key":"3846_CR207","doi-asserted-by":"publisher","first-page":"12317","DOI":"10.3390\/ijms241512317","volume":"24","author":"W Wei","year":"2023","unstructured":"Wei W, Chen Z-N, Wang K. CRISPR\/Cas9: A powerful strategy to improve CAR-T cell persistence. Int J Mol Sci. 2023;24(15):12317.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"3846_CR208","doi-asserted-by":"publisher","first-page":"998","DOI":"10.3390\/cells9040998","volume":"9","author":"T Nakazawa","year":"2020","unstructured":"Nakazawa T, Natsume A, Nishimura F, Morimoto T, Matsuda R, Nakamura M, et al. Effect of CRISPR\/Cas9-mediated PD-1-disrupted primary human third-generation CAR-T cells targeting EGFRvIII on in vitro human glioblastoma cell growth. Cells. 2020;9(4):998.","journal-title":"Cells"},{"issue":"16","key":"3846_CR209","doi-asserted-by":"publisher","first-page":"4692","DOI":"10.1158\/0008-5472.CAN-18-0030","volume":"78","author":"I-Y Jung","year":"2018","unstructured":"Jung I-Y, Kim Y-Y, Yu H-S, Lee M, Kim S, Lee J. CRISPR\/Cas9-mediated knockout of DGK improves antitumor activities of human T cells. Cancer Res. 2018;78(16):4692\u2013703.","journal-title":"Cancer Res"},{"issue":"3","key":"3846_CR210","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s12033-022-00567-0","volume":"65","author":"VE Hillary","year":"2023","unstructured":"Hillary VE, Ceasar SA. A review on the mechanism and applications of CRISPR\/Cas9\/Cas12\/Cas13\/Cas14 proteins utilized for genome engineering. Mol Biotechnol. 2023;65(3):311\u201325.","journal-title":"Mol Biotechnol"},{"key":"3846_CR211","doi-asserted-by":"crossref","unstructured":"Moradi V, Khodabandehloo E, Alidadi M, Omidkhoda A, Ahmadbeigi N. Progress and pitfalls of gene editing technology in CAR-T cell therapy: a state-of-the-art review. Front Oncol. 2024;14.","DOI":"10.3389\/fonc.2024.1388475"},{"key":"3846_CR212","doi-asserted-by":"publisher","first-page":"809754","DOI":"10.3389\/fonc.2022.809754","volume":"12","author":"T Xin","year":"2022","unstructured":"Xin T, Cheng L, Zhou C, Zhao Y, Hu Z, Wu X. In-vivo induced CAR-T cell for the potential breakthrough to overcome the barriers of current CAR-T cell therapy. Front Oncol. 2022;12:809754.","journal-title":"Front Oncol"},{"issue":"43","key":"3846_CR213","doi-asserted-by":"publisher","first-page":"2103258","DOI":"10.1002\/adma.202103258","volume":"33","author":"M Kang","year":"2021","unstructured":"Kang M, Lee SH, Kwon M, Byun J, Kim D, Kim C, et al. Nanocomplex-mediated in vivo programming to chimeric antigen receptor-M1 macrophages for cancer therapy. Adv Mater. 2021;33(43):2103258.","journal-title":"Adv Mater"},{"key":"3846_CR214","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jconrel.2022.01.049","volume":"343","author":"B Han","year":"2022","unstructured":"Han B, Song Y, Park J, Doh J. Nanomaterials to improve cancer immunotherapy based on ex vivo engineered T cells and NK cells. J Controlled Release. 2022;343:379\u201391.","journal-title":"J Controlled Release"},{"key":"3846_CR215","doi-asserted-by":"crossref","unstructured":"Long J, Wang Y, Jiang X, Ge J, Chen M, Zheng B et al. Nanomaterials boost CAR-T therapy for solid tumors. Adv Healthc Mater. 2024;2304615.","DOI":"10.1002\/adhm.202304615"},{"issue":"22","key":"3846_CR216","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1001\/jama.2017.14585","volume":"318","author":"B Ehteshami Bejnordi","year":"2017","unstructured":"Ehteshami Bejnordi B, Veta M, van Johannes P, van Ginneken B, Karssemeijer N, Litjens G, et al. Diagnostic assessment of deep learning algorithms for detection of lymph node metastases in women with breast Cancer. JAMA. 2017;318(22):2199\u2013210.","journal-title":"JAMA"},{"key":"3846_CR217","doi-asserted-by":"crossref","unstructured":"Hsu JB, Lee GA, Chang TH, Huang SW, Le NQK, Chen YC et al. Radiomic immunophenotyping of GSEA-Assessed immunophenotypes of glioblastoma and its implications for prognosis: A feasibility study. Cancers (Basel). 2020;12(10).","DOI":"10.3390\/cancers12103039"},{"issue":"6625","key":"3846_CR218","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1126\/science.abq0225","volume":"378","author":"KG Daniels","year":"2022","unstructured":"Daniels KG, Wang S, Simic MS, Bhargava HK, Capponi S, Tonai Y, et al. Decoding CAR T cell phenotype using combinatorial signaling motif libraries and machine learning. Science. 2022;378(6625):1194\u2013200.","journal-title":"Science"},{"key":"3846_CR219","doi-asserted-by":"crossref","unstructured":"de Godoy LL, Chawla S, Brem S, Mohan S. Taming glioblastoma in real time: integrating multimodal advanced neuroimaging\/ai tools towards creating a robust and therapy agnostic model for response assessment in Neuro-Oncology. Clin Cancer Res. 2023;OF1\u20135.","DOI":"10.1158\/1078-0432.CCR-23-0009"},{"issue":"10","key":"3846_CR220","doi-asserted-by":"publisher","first-page":"e707","DOI":"10.1016\/j.crad.2023.05.022","volume":"78","author":"R Huang","year":"2023","unstructured":"Huang R, Geng H, Zhu L, Yan J, Li C, Li Y. CT radiomics can predict disease progression within 6 months after chimeric antigen receptor-modified T-cell therapy in relapsed\/refractory B-cell non-Hodgkin\u2019s lymphoma patients. Clin Radiol. 2023;78(10):e707\u201317.","journal-title":"Clin Radiol"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-025-03846-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-025-03846-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-025-03846-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T05:05:50Z","timestamp":1757307950000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-025-03846-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":220,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3846"],"URL":"https:\/\/doi.org\/10.1186\/s12935-025-03846-3","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"26 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors and institutions have confirmed this manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"289"}}